Shares of Applied DNA Sciences Inc. (APDN) are soaring over 70% in pre-market today, after the company announced the completion of design qualification, production and shipment of five COVID-19 vaccine candidates to Italy-based Takis Biotech, a developer of cancer vaccines and the company's COVID-19 vaccine development partner, to support preclinical animal testing that will begin immediately.
The vaccine candidates were produced by the company's proprietary PCR-based LinearDNA manufacturing systems.
"Preliminary animal test results from the plasmid-based vaccine templates, from which Applied DNA's linear DNA-based vaccine constructs were manufactured at scale, were immunogenic and induced a strong production of antibodies across all five vaccine candidates," said Dr. Luigi Aurisicchio, CEO and CSO of Takis Biotech.
The stock has been trading between $2.52 and $33.60 in the past one year, and closed Tuesday's trade at $4.55, up 51 cents or 12.62%. APDN is currently trading at $7.78, up $3.23 or 70.99% in the pre-market trading session.
For comments and feedback contact: editorial@rttnews.com
Business News